Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verastem Inc (NQ: VSTM )

3.400 +0.080 (+2.41%)
Streaming Delayed Price Updated: 1:04 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 110,756
Open 3.330
Bid (Size) 3.390 (3)
Ask (Size) 3.410 (11)
Prev. Close 3.320
Today's Range 3.260 - 3.400
52wk Range 2.600 - 14.22
Shares Outstanding 25,325,551
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a KRAS G12D (ON/OFF) Inhibitor, in a Phase 1/2 Trial in China as Part of Collaboration with GenFleet Therapeutics
From Verastem Oncology
Via Business Wire

Performance

YTD
-59.04%
-59.04%
1 Month
+7.59%
+7.59%
3 Month
-65.09%
-65.09%
6 Month
-68.02%
-68.02%
1 Year
-64.80%
-64.80%

More News

Read More
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
VSTM Stock Earnings: Verastem Beats EPS for Q1 2024
Via InvestorPlace
Verastem Oncology Announces Addition to Russell 3000® and Russell Microcap® Indexes
From Verastem Oncology
Via Business Wire
VERASTEM ALERT: Bragar Eagel & Squire, P.C. is Investigating Verastem, Inc. on Behalf of Verastem Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Verastem, Inc. (VSTM)
From Kirby McInerney LLP
Via Business Wire
7 F-Rated Stocks to Avoid at All Costs in June
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Crude Oil Rises 1%; Verastem Shares Slide
Via Benzinga
Exposures Fossil Fuels
Why NetEase Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Nasdaq Gains 1%; Intuit Shares Plunge
Via Benzinga
Is the Stock Market Open on Memorial Day 2024?
Via InvestorPlace
7 Things to Know About the Upcoming Nvidia (NVDA) Stock Split
Via InvestorPlace
NLST Stock Alert: Micron Faces $445 Million Verdict in Netlist Patent Trial
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
Why Is Verastem (VSTM) Stock Down 62% Today?
Via InvestorPlace
Dow Surges 50 Points; US Durable Goods Orders Increase In April
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?
Via Benzinga
Exposures Product Safety
Why Ross Stores Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer​
From Verastem Oncology
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.